I think of JBI and their creation of P2O similarly to how I think of a pharmaceutical company creating a new drug. Lots of trial and error when you are dealing with "unknowns", but when you get it right, it has massive payoff and ROI. It is amazing how much JBI has accomplished with $60 million...especially when you compare it to the $350 million minimum a pharma company spends on creating a single drug. "Johnson & Johnson, which had the most new drugs approved spent $5.2 billion per drug."
JBI's table-top unit was their phase I clinical study, processor #2 was JBI's equivalent of phase II, and JBI's Processor #3 with new improvements was their Phase III study and was proven to work and approved by the NY DEC, US Steel,Crayola, and other 3rd party entities. Now they are in the roll-out phase. It's just a matter of time before they finalize processor sales. In the mean time, they will continue to cure Crayola's ailments.
"A company hoping to get a single drug to market can expect to have spent $350 million before the medicine is available for sale. In part because so many drugs fail, large pharmaceutical companies that are working on dozens of drug projects at once spend $5 billion per new medicine."
News 
Market Data 
Discover 
